MCRB — Seres Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1609809 ·
Last close
$1.41
Market Cap
$14.37M
52W High
$29.98
52W Low
$1.30
ADV30
86,812
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | 0 | -10,447,000 | -16,286,000 | 65,888,000 | 17,528,000 | 44,529,000 |
| Jun 2026 | 736,000 | 736,000 | -15,466,000 | 4,581,000 | 101,588,000 | 15,594,000 | 67,054,000 |
| Mar 2026 | 358,000 | 358,000 | -20,907,000 | -19,913,000 | 117,618,000 | 29,834,000 | 91,119,000 |
| Dec 2025 | 789,000 | 197,000 | -19,377,000 | -15,335,000 | 138,193,000 | 45,766,000 | 93,975,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-63,941,000
Investing CF
$12,747,000
Financing CF
$15,552,000
CapEx
$-252,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.30
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,004,021,000
Inventory
—
Receivables
$12,683,000
ST Investments
—
EBIT TTM
$33,470,000
Pretax Income TTM
$-46,953,000
Interest Exp TTM
$0
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,883,000
EBITDA
$-74,778,000
Free Cash Flow
$-64,600,876
Enterprise Value
$61,827,236
Total Cash
$15,594,000
Total Debt
$56,644,000
Shares Out
10,195,031
Trailing EPS
$-5.01
Book Value
$4.63
ROE
-66.6%
ROA
-39.8%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 789,000 | -93,971,000 | 5,696,000 | 138,193,000 | 93,975,000 | 44,218,000 | 1,117,000 |
| Dec 2024 | 0 | -121,315,000 | 136,000 | 139,810,000 | 126,026,000 | 13,784,000 | -148,609,000 |
| Dec 2023 | 0 | -195,097,000 | -113,724,000 | 358,600,000 | 403,456,000 | -44,856,000 | -117,354,000 |
| Dec 2022 | 0 | -179,914,000 | -250,157,000 | 348,784,000 | 338,001,000 | 10,783,000 | -228,816,000 |
TTM Snapshot
Revenues TTM
$719,000
NetIncome TTM
$-22,463,000
OpCashFlow TTM
—
Assets (Latest)
$101,588,000
Forward EPS
$-4.39
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $1.00 · spot: $1.44 · call volume: 35 · put volume: 3
Expected Move to 2027-01-15:
±$1.50
(104.17%) —
implied range
$-0.06 –
$2.94
· ATM straddle on $1.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CTXR | Citius Pharmaceuticals, Inc. | $14.24M | $0.52 | — |
| KTTA | Pasithea Therapeutics Corp. | $14.51M | $0.43 | — |
| BOLT | Bolt Biotherapeutics, Inc. | $14.73M | $5.65 | — |
| MDNAF | Medicenna Therapeutics Corp. | $14.77M | $0.16 | — |
| INTI | Inhibitor Therapeutics, Inc. | $13.98M | $0.08 | — |
News headlines (Yahoo Finance, 1h cache)
Seres Therapeutics (MCRB) Reports Q3 Loss, Beats Revenue Estimates
2026-11-04 12:55 · Yahoo
Seres Therapeutics: Q3 Earnings Snapshot
2026-11-04 12:12 · Yahoo
Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC)
2026-11-04 12:00 · Yahoo
Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients
2026-11-03 12:00 · Yahoo
Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026
2026-10-15 11:00 · Yahoo
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-08 22:00 · Yahoo
Microbiome Therapeutics Market Report 2026-2035 Featuring Profiles of Ferring Pharmaceuticals, Infant Bacterial Therapeutics, MaaT Pharma, Mikrobiomik, Seres Therapeutics, Vedanta Biosciences
2026-09-07 08:27 · Yahoo
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
2026-09-01 11:00 · Yahoo
Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs
2026-08-05 11:00 · Yahoo
Seres Therapeutics’ SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study
2026-07-10 18:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.